Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

Seminars in Liver Disease

Volumn 23, Issue 2, 2003, Pages 173-181

  Kontorinis, Nickolas ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Coinfection; Delaviridine; Efavirenz; Hepatotoxicity; HIV infection; Hypersensitivity reaction; Nevirapine; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CIMETIDINE; DELAVIRDINE; EFAVIRENZ; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; KETOCONAZOLE; MACROLIDE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ARTICLE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG TOLERABILITY; FATTY LIVER; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LIPODYSTROPHY; LIVER TOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RASH; SUBSTANCE ABUSE; SUPERINFECTION; TERATOGENICITY; VIROLOGY; VIRUS HEPATITIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELAVIRDINE; HIV INFECTIONS; HUMANS; LIVER DISEASES; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037945435     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39948     Document Type: Article

References (39)

1. Kreisberg R. Clinical problem-solving. We blew it. N Engl J Med 1995;332:945-949
2. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in co-infection. Am J Med 1999; 107:79S-84S
3. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998;12:1256
4. AIDS Clinical Trials Group criteria, Division of AIDS. Table for grading severity of adult adverse experiences, August 1992
5. Lewis W, Dalakas MC. Mitochondrial toxicity of antiretroviral drugs. Nat Med 1995;1:417-422
6. Moyle G. Toxicity of antiretroviral nucleoside and nonnucleoside analogues. Is mitochondrial toxicity the only mechanism? Drug Saf 2000;23:467-481
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51
8. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254
9. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002;36: 283-294
10. Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case and review of the literature. Am J Med 1992;93: 94-96
11. Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998;351:567
12. Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-1443
13. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1245-1231
14. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U. S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep 1999;48:32-34
15. Melvin DC, Lee JK, Belsey E, et al. The impact of coinfection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000;14:463-446
16. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902
17. Greub G, Lederberger B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356: 1800-1805
18. Monforte Ade A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV co-infection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114-123
19. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-247
20. Núñez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27: 426-431
21. Rutschman OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients co-infected with HIV. J Infect Dis 1998;177:783-785
22. Pfister M, Labbe L, Hammer SM, et al. Population Pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47:130-137
23. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002;19:1038-1045
24. Clark SJ, Creighton S, Portmann B, et al. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 2002;36:295-301
25. Dieterich D, Stern J, Robinson P, et al. Analyses of 4 key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4 + levels, hepatitis B & C seropositivity and baseline liver function tests. In: Program and Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment. July 8-11, 2001; Buenos Aires, Argentina. Abstract 44
26. Stern JO, et al. Hepatic safety of nevirapine: results of the Boehringer Ingelheim viramune hepatic safety project. Presented at the 14th International AIDS conference. July 7-12, 2002; Barcelona, Spain. LBOr15 (postor presentation)
27. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235
28. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-1154
29. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124-129
30. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-188
31. Lebray P, Benhamou Y, Pol S, et al. NNRTI-related or -unrelated hepatotoxicity? Hepatology 2002;36:512-513
32. Palmon R, Koo BCA, Shoultz DA, et al. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:340-345
33. Clarke S, Harrington P, Condon C, et al. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000;11:336-337
34. van Leth F, Hassink E, Phanphk P, et al. Results of the 2NN study: a randomized comparative trial of first line antitretiviral therapy with regimens containing either nevirapine alone, efavirenz alone, or both drugs combined together with stavudine and lamivudine. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, February 2003; Boston, MA. Abstract 176
35. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268
36. Reisler R, Servoss JC, Sherman KE, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. In: Program and Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment. July 8-11, 2001; Buenos Aires, Argentina. Abstract 43
37. Abrescia N, D'Abbraccio M, Figoni M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002;50:763-765
38. Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16: 2183-2193
39. van der Valk M, Kastelein JJ, Murphy RL, et al. The Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414